Focus: AstraZeneca is a global Big Pharma company with ~90,000 employees headquartered in Cambridge, UK, competing across oncology, cardiovascular, respiratory, immunology, and rare diseases. The company maintains a diversified portfolio of small molecules, biologics, and vaccines with peak-stage blockbusters generating billions in annual revenue.
Profile data last refreshed 22h ago · AI intelligence enriched 4w ago
Hot — 2770 jobs added in 30d
Net +1770 (2770 new, 1000 removed). Aggressive expansion phase.
AstraZeneca is a stable, large-scale career home for professionals seeking oncology/immunology depth and cross-functional growth, but patent cliff exposure requires candid discussion about 2031–2035 product transition strategies.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AstraZeneca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AstraZeneca's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Anchor franchise representing 37% of company revenue; extends market exclusivity through 2041, anchoring near-term financial stability.
Major respiratory franchise facing approaching loss of exclusivity; represents key exposure to generic erosion pressure.
Peak-stage oncology asset targeting Btk inhibition; patent protection until 2036 supports sustained cash generation in competitive hematology market.
Cornerstone EGFR TKI in lung cancer with 51 active trials; patent protection extended to 2042 and supported by robust Phase 4 development.
Respiratory triple-therapy agent capturing growing COPD market share; patent protection through 2038 provides solid revenue runway.
Cardiovascular antiplatelet agent with patent protection through 2036; sustained by established clinical evidence and physician adoption.
PARP inhibitor with 44 active development programs supporting label expansion; early patent cliff (2031) creates near-term revenue risk and restructuring headwind.
Long-acting GLP-1 formulation facing aggressive patent cliff by 2031; revenue concentration is eroding as next-generation competitors gain market share.
Rare disease biologic with no patent cliff date; signals company commitment to niche-market specialization and premium pricing.
Pioneering complement inhibitor losing market share to newer agents (ravulizumab) and generics; demonstrates continued exposure to biologic competition.
108 discontinued, 26 duplicate formulations not shown
+15 more products with revenue data
+2 more
AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know - Stocktwits
AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know Stocktwits
astrazeneca acquired rights to cspc experimental weight-loss drugs for billions - Meteo.gr
astrazeneca acquired rights to cspc experimental weight-loss drugs for billions Meteo.gr
AstraZeneca is a British behemoth. Why is it turning to America? - The Times
AstraZeneca is a British behemoth. Why is it turning to America? The Times
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts - TradingView
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts TradingView
AstraZeneca, insitro Sign AI Drug Discovery Deal - Contract Pharma
AstraZeneca, insitro Sign AI Drug Discovery Deal Contract Pharma
AstraZeneca partners with AI biotech insitro on liver, heart drugs - Quartz
AstraZeneca partners with AI biotech insitro on liver, heart drugs Quartz
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+13 more products
+2 more
+2 more
+2 more
+2 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo